|This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. (November 2014)|
|Traded as||NASDAQ: PRXL|
|Industry||Clinical research organizations
|Headquarters||Waltham, Massachusetts, United States of America;
76+ facilities in 50+ countries
|Chairman and CEO:
Josef H. von Rickenbach
|Services||clinical trial management, data management, medical writing, biostatistics, pharmacovigilance, regulatory consulting|
|Revenue||$1.734B for FY13|
Number of employees
PAREXEL International Corporation is a multinational biopharmaceutical contract research organization that provides clinical research, clinical logistics, medical communications, consulting, and advanced technology products and services to pharmaceutical, biotechnology, and medical device industries worldwide. The name PAREXEL comes from Paracelsus, a Swiss physician considered as the father of modern toxicology. PAREXEL employs more than 15,000 people worldwide in over 50 countries and helps leading biotechnology companies and several large pharmaceutical companies bring new products to the market.
The company provides services during all phases of a product’s development, from planning to commercialization. This includes strategy development, clinical trials management, data management, biostatistical analysis, regulatory affairs, drug development consulting, medical marketing, training, publishing and advanced eClinical technology solutions.
||The neutrality of this section is disputed. (February 2015)|
In March 2006, a PAREXEL-run trial on behalf of TeGenero, the now bankrupt German biotechnology firm, on its anti-inflammatory drug TGN1412 to treat rheumatoid arthritis, multiple sclerosis or leukaemia, unexpectedly caused severe inflammation and multiple organ failure in six healthy volunteers at a facility based at Northwick Park Hospital in London.The drug had been tested on animals but this was the first test on humans.
PAREXEL became the target of legal proceedings from lawyers representing the injured volunteers after the insurance policy of TeGenero was unable to provide sufficient compensation. When the liable company subsequently declared bankruptcy, lawyers for the volunteers initiated legal proceeding against PAREXEL and the two parties later entered into talks; the results of this meeting have not been made public.
A documentary shown in the UK on 28 September 2006 featuring journalist Brian Deer as part of Channel 4's Dispatches series exposed uncertainty about the existence of data that should mandatorily have been submitted by TeGenero to the Medicines and Healthcare products Regulatory Agency (MHRA) prior to the trial indicating whether TGN1412 had been adequately tested on human blood in vitro. Concerns were also raised about whether a safe human dosage was properly obtained by TeGenero. The MHRA however concluded that none of the companies involved could be held responsible for the outcome of the test and that the adverse events that occurred were most likely caused by an unpredicted biological action of the drug in humans.
- "History of PAREXEL". PAREXEL. Archived from the original on 2007-10-19. Retrieved 2007-12-28.